Treatment guidelines – Treatment access

Oliviu Pascu

Treatment of chronic hepatitis C in Romania

- 2003-2015: Interferon based treatment
- 2016: Treatment of compensated cirrhosis with DAA
- 2017: Treatment of chronic hepatitis (F3), compensated cirrhosis (F4) and decompensated cirrhosis with DAA.



2000- 5000 patients /year
Hepatitis F2-F3-F4
Selected centers –Central Committee for approval

I. Interferon based terapy

| No of patients | Severity assessment | SVR | nonresponders |
|----------------|------------------------|--------|----------------|
| 56 000 | Liver biopsy | 48-50% | ~30 000 |

II.2016-Compensated Cirrhosis Ombitasvir+Paritaprevir+ Ritonavir + Dasabuvir

| No patients | Severity assesment | | prescribing physicians |
|-------------|-----------------------|-------|---------------------------|
| 6000 | LB- Fibromax | › 99% | 11 centers (G-ID) |

III. 2017-Chronic Hepatitis (f3)-compensated cirrhosis(f4) (Ombitasvir+Paritaprevir+ Ritonavir + Dasabuvir)

| No of approved patients | No of treated patients | SVR | prescribing physicians |
|-------------------------|------------------------|-----|---------------------------|
| 10 000 | 7000 | 99% | 11 centers (G+ID) |
| | | | |

III.2017-Decompensated cirrhosis (Sofosbuvir+Ledipasvir)

| No of approved patients | No of treated patients | SVR | prescribing physicians |
|-------------------------|------------------------|--------|---------------------------|
| 2000 | 700 | 90-95% | 11 centers (G) |

The future: 2018-2019

- We asked MH to change the low- cost-volume- because we only had one molecule available. The low was changed- and probably we will have 2 or 3 molecules(combination)
- We intend to include patients with F1 and F2 without discrimination.
- We intend to recommend the extensive use of non-invasive and inexpensive assessment methods: Fibroscan, APRI
- We want to extend the area of prescriptions to all county hospitals
- We intend to make a simple and easy to apply Protocol

EASL-2016

hepatocellular carcinoma (HCC). The number of chronically infected persons worldwide is estimated to be about <u>180 million</u>.

Where 110 million disappeared in 2 years?

EASL-2018

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately <u>71</u> million chronically infected individuals worldwide. Clinical care for patients with

It's the same situation in Romania?

- We had 30000 non-responders in 2015
- We found only 13,000 patients(2016-2017) to be included in treatment
- 17,000 have disappeared
- If the proportion remains, we may have only 150,000 to 200,000 infected patients not 500,000- 600,000
- This requires adaptation of the screening and treatment strategy.

Thank you very much